Related Experiment Video

Updated: Sep 6, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K

Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2-Mediated Suppression of NLRP3 Inflammasome Activation

Xuan Sun1, Junfeng Duan1, Chenyi Gong1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, Department of Cardiology, Nanjing Drum Tower Hospital Medical School of Nanjing University Nanjing China.

Journal of the American Heart Association
|June 29, 2022
PubMed

Insights

Colchicine treatment improved cardiac function and reduced fibrosis in a mouse model of dilated cardiomyopathy. This anti-inflammatory drug works by upregulating SIRT2, which inactivates the NLRP3 inflammasome, offering a potential therapy for heart failure.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Pharmacology

Background:

  • Dilated cardiomyopathy is a major cause of heart failure globally.
  • Inflammation significantly contributes to heart failure progression, yet effective immunomodulatory treatments are limited.
  • The role of colchicine, an anti-inflammatory drug, in non-ischemic heart failure is not well understood.

Purpose of the Study:

  • To investigate the therapeutic potential of colchicine in a non-ischemic dilated cardiomyopathy model.
  • To elucidate the anti-inflammatory mechanisms of colchicine in the context of heart failure.
  • To explore the role of SIRT2 (Sirtuin 2) and NLRP3 (NOD-like receptor protein 3) inflammasome in colchicine's effects.

Main Methods:

  • A murine model of dilated cardiomyopathy was induced using doxorubicin administration.
  • Mice were treated with colchicine or saline, and cardiac function and fibrosis were assessed.
  • Inflammatory markers, including cytokine levels, neutrophil infiltration, and NLRP3 inflammasome activation, were measured.
  • In vitro experiments involved pharmacological inhibition of SIRT2 to examine its interaction with the NLRP3 inflammasome.

Main Results:

  • Colchicine treatment significantly improved cardiac function and reduced myocardial fibrosis in the dilated cardiomyopathy model.
  • Colchicine decreased neutrophil infiltration and inflammatory cytokine levels in the failing heart.
  • Mechanistically, colchicine was found to upregulate SIRT2 expression, leading to deacetylation and inactivation of the NLRP3 inflammasome.
  • Inhibition of SIRT2 diminished the suppressive effects of colchicine on NLRP3 inflammasome activation.

Conclusions:

  • Colchicine demonstrates significant therapeutic potential for treating dilated cardiomyopathy.
  • The anti-inflammatory effects of colchicine in this model are mediated through the SIRT2-dependent inactivation of the NLRP3 inflammasome.
  • Colchicine may be a promising therapeutic agent for non-ischemic heart failure associated with inflammatory responses.

Keywords:
NLRP3 inflammasomeSIRT2colchicinedilated cardiomyopathyinflammation

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

541

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
23
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K